Renovaro Inc. (NASDAQ:RENB) Stock Holdings Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its stake in Renovaro Inc. (NASDAQ:RENB) by 347.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,010 shares of the company’s stock after purchasing an additional 72,230 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.06% of Renovaro worth $45,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Barclays PLC boosted its position in Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after acquiring an additional 52,804 shares during the period. 71.41% of the stock is currently owned by institutional investors and hedge funds.

Renovaro Stock Performance

Shares of RENB opened at $0.70 on Wednesday. Renovaro Inc. has a 52 week low of $0.40 and a 52 week high of $4.45. The company has a market capitalization of $111.18 million, a PE ratio of -0.73 and a beta of 0.63. The company’s 50 day moving average price is $1.04 and its 200 day moving average price is $0.78.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.